Recent progress in mucosal vaccine development: Potential and limitations

Nature Reviews Immunology

Volumn 12, Issue 8, 2012, Pages 592-605

  Lycke, Nils ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CCL25 CHEMOKINE; CHEMOKINE; CHITOSAN; CHOLERA VACCINE; CVD1208 VACCINE; CYTOKINE; ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LECTIN; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; MUCOSAL VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; SAPONIN; SECRETORY IMMUNOGLOBULIN; SHANCHOL; SWINE INFLUENZA VACCINE; TOLL LIKE RECEPTOR; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE; WATER OIL CREAM;

ANTIBODY RESPONSE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELLULAR IMMUNITY; CHOLERA; DENDRITIC CELL; DRUG EFFICACY; DRUG RESEARCH; EFFECTOR CELL; HERD IMMUNITY; HUMAN; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; INFLUENZA; INFLUENZA A (H1N1); LYMPHOID TISSUE; MEMORY CELL; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; PEYER PATCH; PHAGE DISPLAY; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; ROTAVIRUS INFECTION; SALMONELLOSIS; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; HUMANS; IMMUNITY, MUCOSAL; INFLUENZA VACCINES; MUCOUS MEMBRANE; ROTAVIRUS VACCINES; VACCINATION; VACCINES;

EID: 84864338756     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3251     Document Type: Review

References (157)

1. Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nature Med. 11, S45-S53 (2005). (Pubitemid 40562303)
2. Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: the promise and the challenge. Nature Rev. Immunol. 6, 148-158 (2006). (Pubitemid 43361590)
3. Levine, M. M. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 8, 129 (2010).
4. Walker, R. I. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine 23, 3369-3385 (2005). (Pubitemid 40520524)
5. Levine, M. M. & Dougan, G. Optimism over vaccines administered via mucosal surfaces. Lancet 351, 1375-1376 (1998). (Pubitemid 28209992)
6. Yuki, Y. & Kiyono, H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev. Vaccines 8, 1083-1097 (2009).
7. Amorij, J. P., Hinrichs, W., Frijlink, H. W., Wilschut, J. C. & Huckriede, A. Needle-free influenza vaccination. Lancet Infect. Dis. 10, 699-711 (2010).
8. Burt, D. et al. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations. Expert Rev. Vaccines 10, 365-375 (2011).
9. Carter, N. J. & Curran, M. P. Live attenuated influenza vaccine (FluMist; Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 71, 1591-1622 (2011).
10. Langley, J. M. et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine 29, 1921-1928 (2011).
11. Brandtzaeg, P. Function of mucosa-associated lymphoid tissue in antibody formation. Immunol. Invest. 39, 303-355 (2010).
12. Brandtzaeg, P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25, 5467-5484 (2007). (Pubitemid 47031365)
13. Sheridan, B. S. & Lefrancois, L. Regional and mucosal memory T cells. Nature Immunol. 12, 485-491 (2011).
14. Mora, J. R. & von Andrian, U. H. Role of retinoic acid in the imprinting of gut-homing IgA-secreting cells. Semin. Immunol. 21, 28-35 (2009).
15. Kiyono, H. & Fukuyama, S. NALT-versus Peyer's-patch-mediated mucosal immunity. Nature Rev. Immunol. 4, 699-710 (2004). (Pubitemid 39223076)
16. Mowat, A. M., Millington, O. R. & Chirdo, F. G. Anatomical and cellular basis of immunity and tolerance in the intestine. J. Pediatr. Gastroenterol. Nutr. 39, S723-S724 (2004).
17. Brandtzaeg, P. Update on mucosal immunoglobulin A in gastrointestinal disease. Curr. Opin. Gastroenterol. 26, 554-563 (2010).
18. Bevan, M. J. Memory T cells as an occupying force. Eur. J. Immunol. 41, 1192-1195 (2011).
19. Blaschitz, C. & Raffatellu, M. Th17 cytokines and the gut mucosal barrier. J. Clin. Immunol. 30, 196-203 (2010).
20. Feng, T. & Elson, C. O. Adaptive immunity in the host-microbiota dialog. Mucosal Immunol. 4, 15-21 (2011).
21. Slack, E. et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 325, 617-620 (2009).
22. Czerkinsky, C. & Holmgren, J. Enteric vaccines for the developing world: a challenge for mucosal immunology. Mucosal Immunol. 2, 284-287 (2009).
23. Manicassamy, S. & Pulendran, B. Modulation of adaptive immunity with Toll-like receptors. Semin. Immunol. 21, 185-193 (2009).
24. Tucker, S. N., Tingley, D. W. & Scallan, C. D. Oral adenoviral-based vaccines: historical perspective and future opportunity. Expert Rev. Vaccines 7, 25-31 (2008). (Pubitemid 351357964)
25. Pasetti, M. F., Simon, J. K., Sztein, M. B. & Levine, M. M. Immunology of gut mucosal vaccines. Immunol. Rev. 239, 125-148 (2011).
26. Lycke, N. in Vaccine adjuvants and delivery systems (ed. Singh, M.) 53-79 (John Wiley & Sons, 2007).
27. Greenberg, H. B. & Estes, M. K. Rotaviruses: from pathogenesis to vaccination. Gastroenterology 136, 1939-1951 (2009).
28. Ruiz-Palacios, G. M. et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. 354, 11-22 (2006). (Pubitemid 43048947)
29. Kirkpatrick, B. D. et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 24, 116-123 (2006). (Pubitemid 41752998)
30. Li, R., Lim, A. & Alonso, S. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route. Bioeng. Bugs 2, 315-319 (2011).
31. Simon, J. K. et al. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. Clin. Immunol. 139, 185-192 (2011).
32. Tribble, D. et al. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers. Vaccine 28, 6076-6085 (2010).
33. El-Kamary, S. S. et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202, 1649-1658 (2010).
34. Heinonen, S. et al. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect. Dis. 11, 23-29 (2011).
35. DeRoeck, D. et al. Typhoid vaccination: the Asian experience. Expert Rev. Vaccines 7, 547-560 (2008). (Pubitemid 351881339)
36. Shin, S., Desai, S. N., Sah, B. K. & Clemens, J. D. Oral vaccines against cholera. Clin. Infect. Dis. 52, 1343-1349 (2011).
37. Zakay-Rones, Z. Human influenza vaccines and assessment of immunogenicity. Expert Rev. Vaccines 9, 1423-1439 (2010).
38. Madhi, S. A. et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N. Engl. J. Med. 362, 289-298 (2010).
39. Vesikari, T. et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354, 23-33 (2006). (Pubitemid 43048948)
40. Grimwood, K. & Forbes, D. A. Acute and persistent diarrhea. Pediatr. Clin. North Am. 56, 1343-1361 (2009).
41. + dendritic cells with the ability to generate gut-tropic T cells. Mucosal Immunol. 4, 438-447 (2011).
42. Cooper, P. J. et al. Impact of early life exposures to geohelminth infections on the development of vaccine immunity, allergic sensitization, and allergic inflammatory diseases in children living in tropical Ecuador: the ECUAVIDA birth cohort study. BMC Infect. Dis. 11, 184 (2011).
43. Holmgren, J. Actions of cholera toxin and the prevention and treatment of cholera. Nature 292, 413-417 (1981). (Pubitemid 11013851)
44. Quiding, M. et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-γ production and evokes local immunological memory. J. Clin. Invest. 88, 143-148 (1991).
45. Shamsuzzaman, S. et al. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses. Vaccine 27, 1386-1392 (2009).
46. Svennerholm, A. M. & Holmgren, J. Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea. Adv. Exp. Med. Biol. 371B, 1623-1628 (1995).
47. Ali, M. et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366, 44-49 (2005). (Pubitemid 40956529)
48. Wijburg, O. L. et al. Innate secretory antibodies protect against natural Salmonella typhimurium infection. J. Exp. Med. 203, 21-26 (2006). (Pubitemid 43139640)
49. Czerkinsky, C. & Holmgren, J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr. Top. Microbiol. Immunol. 354, 1-18 (2010).
50. Chadwick, S., Kriegel, C. & Amiji, M. Nanotechnology solutions for mucosal immunization. Adv. Drug Deliv. Rev. 62, 394-407 (2010).
51. Peek, L. J., Middaugh, C. R. & Berkland, C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60, 915-928 (2008).
52. Brandtzaeg, P. Potential of nasopharynx-associated lymphoid tissue for vaccine responses in the airways. Am. J. Respir. Crit. Care Med. 183, 1595-1604 (2011).
53. Jabbal-Gill, I. Nasal vaccine innovation. J. Drug Target. 18, 771-786 (2010).
54. Kreijtz, J. H., Fouchier, R. A. & Rimmelzwaan, G. F. Immune responses to influenza virus infection. Virus Res. 162, 19-30 (2011).
55. Bakke, H. et al. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. Scand. J. Immunol. 63, 223-231 (2006). (Pubitemid 43356784)
56. Djupesland, P. G. & Skretting, A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J. Aerosol Med. Pulm. Drug Deliv. 17 Jan 2012 (doi:10.1089/jamp.2011.0924) .
57. Mestecky, J., Alexander, R. C., Wei, Q. & Moldoveanu, Z. Methods for evaluation of humoral immune responses in human genital tract secretions. Am. J. Reprod. Immunol. 65, 361-367 (2011).
58. Bomsel, M. et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34, 269-280 (2011).
59. Lopalco, L. & Bomsel, M. Protecting the initial site of viral entry: an alternative HIV vaccine target. Expert Rev. Vaccines 10, 1253-1256 (2011).
60. + T cell immunity in the female genital tract is critically dependent on local mucosal immunization. Eur. J. Immunol. 41, 2642-2653 (2011).
61. Wegmann, F. Mucosally-targeted HIV-1 vaccines. Hum. Vaccin. 7, 982-985 (2011).
62. Lewis, D. J. et al. Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS ONE 6, e25165 (2011).
63. Czerkinsky, C., Cuburu, N., Kweon, M. N., Anjuere, F. & Holmgren, J. Sublingual vaccination. Hum. Vaccin. 7, 110-114 (2011).
64. Kweon, M. N. Sublingual mucosa: a new vaccination route for systemic and mucosal immunity. Cytokine 54, 1-5 (2011).
65. Carmichael, J. R., Pal, S., Tifrea, D. & de la Maza, L. M. Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine 29, 5276-5283 (2011).
66. Cho, H. J. et al. Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. Vaccine 28, 2598-2606 (2010).
67. Domm, W. et al. Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier. Vaccine 29, 7080-7089 (2011).
68. Song, J. H. et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl Acad. Sci. USA 105, 1644-1649 (2008).
69. Flach, C. F. et al. A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori. Vaccine 29, 1235-1241 (2011).
70. Huo, Z. et al. Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PLoS ONE 7, e33736 (2012).
71. van der Lubben, I. M., Verhoef, J. C., Borchard, G. & Junginger, H. E. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 52, 139-144 (2001). (Pubitemid 33079169)
72. Garg, N. K., Mangal, S., Khambete, H. & Tyagi, R. K. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat. Drug Deliv. Formul. 4, 114-128 (2010).
73. Wassen, L., Schon, K., Holmgren, J., Jertborn, M. & Lycke, N. Local intravaginal vaccination of the female genital tract. Scand. J. Immunol. 44, 408-414 (1996). (Pubitemid 26327025)
74. Eliasson, D. G. et al. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine 29, 3951-3961 (2011).
75. Ishii, M. & Kojima, N. Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization. Glycoconj. J. 27, 115-123 (2010).
76. Schneider-Ohrum, K. & Ross, T. M. Virus-like particles for antigen delivery at mucosal surfaces. Curr. Top. Microbiol. Immunol. 354, 53-73 (2011).
77. Kuolee, R. & Chen, W. M cell-targeted delivery of vaccines and therapeutics. Expert Opin. Drug Deliv. 5, 693-702 (2008). (Pubitemid 351998258)
78. Kelsall, B. Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages. Mucosal Immunol. 1, 460-469 (2008).
79. Azizi, A., Kumar, A., Diaz-Mitoma, F. & Mestecky, J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog. 6, e1001147 (2010).
80. Galli, G. et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106, 7962-7967 (2009).
81. Dormitzer, P. R. et al. Influenza vaccine immunology. Immunol. Rev. 239, 167-177 (2011).
82. Elson, C. O. & Dertzbaugh, M. T. in Mucosal Immunology (eds Mestecky, J. et al.) 967-986 (Elsevier Academic Press, 2005).
83. Lambrecht, B. N., Kool, M., Willart, M. A. & Hammad, H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21, 23-29 (2009).
84. Harandi, A. M. & Medaglini, D. Mucosal adjuvants. Curr. HIV Res. 8, 330-335 (2010).
85. Blaas, S. H., Stieber-Gunckel, M., Falk, W., Obermeier, F. & Rogler, G. CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. Clin. Exp. Immunol. 155, 534-540 (2009).
86. Uematsu, S. et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nature Immunol. 9, 769-776 (2008). (Pubitemid 351859160)
87. Boyaka, P. N. et al. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. J. Immunol. 166, 2283-2290 (2001). (Pubitemid 32173459)
88. Christensen, D. et al. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J. Liposome Res. 19, 2-11 (2009).
89. Kool, M. et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181, 3755-3759 (2008).
90. Malyala, P. et al. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J. Pharm. Sci. 97, 1155-1164 (2008).
91. Freytag, L. C., Clements, J. D., Grdic Eliasson, D. & Lycke, N. in New Generation Vaccines (ed. Levine, M.M.) 273-283 (Informa, 2010).
92. Liang, S. & Hajishengallis, G. Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. Immunol. Invest. 39, 449-467 (2010).
93. Spangler, B. D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56, 622-647 (1992).
94. + T cells and generation of specific antibodies following mucosal immunization. J. Immunol. 183, 5032-5041 (2009).
95. Connell, T. D. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev. Vaccines 6, 821-834 (2007). (Pubitemid 47607856)
96. Snider, D. P. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 15, 317-348 (1995). (Pubitemid 26259134)
97. Anosova, N. G. et al. Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches. Mucosal Immunol. 1, 59-67 (2008).
98. Fujihashi, K., Koga, T., van Ginkel, F. W., Hagiwara, Y. & McGhee, J. R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20, 2431-2438 (2002). (Pubitemid 34615580)
99. Glueck, R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 20, S42-S44 (2001). (Pubitemid 32925007)
100. Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350, 896-903 (2004). (Pubitemid 38252537)
101. Levine, M. M. et al. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect. Immun. 43, 515-522 (1984). (Pubitemid 14181594)
102. Pizza, M. et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19, 2534-2541 (2001). (Pubitemid 32234269)
103. Summerton, N. A. et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28, 1404-1411 (2010).
104. Brereton, C. F. et al. Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J. Immunol. 186, 5896-5906 (2011).
105. Lewis, D. J. et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 4, e6999 (2009).
106. Hagiwara, Y. et al. A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J. Immunol. 177, 3045-3054 (2006). (Pubitemid 44277821)
107. Agren, L. C., Ekman, L., Lowenadler, B. & Lycke, N. Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158, 3936-3946 (1997). (Pubitemid 127488754)
108. Lycke, N. & Bemark, M. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Mucosal Immunol. 3, 556-566 (2010).
109. Eriksson, A. M., Schon, K. M. & Lycke, N. Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 173, 3310-3319 (2004). (Pubitemid 39142040)
110. Sundling, C. et al. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J. Gen. Virol. 89, 2954-2964 (2008).
111. Hasselberg, A., Schon, K., Tarkowski, A. & Lycke, N. Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis. Arthritis Rheum. 60, 1672-1682 (2009).
112. Hasselberg, A., Ekman, L., Yrlid, L. F., Schon, K. & Lycke, N. Y. ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization. J. Immunol. 184, 2776-2784 (2010).
113. Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055-1065 (2010).
114. Alam, M. M. et al. Antigen-specific memory B-cell responses in Bangladeshi adults after one-or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin. Vaccine Immunol. 18, 844-850 (2011).
115. Di Fabio, S. et al. Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine 16, 485-492 (1998). (Pubitemid 28044166)
116. Rudenko, L. et al. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 29, A40-A44 (2011).
117. Tengvall, S., Lundgren, A., Quiding-Jarbrink, M. & Svennerholm, A. M. BAFF, stimulatory DNA and IL-15 stimulates IgA+ memory B cells and provides a novel approach for analysis of memory responses to mucosal vaccines. Vaccine 28, 5445-5450 (2010).
118. Lycke, N. & Holmgren, J. Long-term cholera antitoxin memory in the gut can be triggered to antibody formation associated with protection within hours of an oral challenge immunization. Scand. J. Immunol. 25, 407-412 (1987).
119. Lycke, N. & Holmgren, J. Adoptive transfer of gut mucosal antitoxin memory by isolated B cells 1 year after oral immunization with cholera toxin. Infect. Immun. 57, 1137-1141 (1989). (Pubitemid 19087859)
120. Bergqvist, P. et al. Re-utilization of germinal centers in multiple Peyer's patches results in highly synchronized, oligoclonal, and affinity-matured gut IgA responses. Mucosal Immunol. 11 Jul 2012 (doi:10.1038/mi.2012.56).
121. Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745-763 (2004). (Pubitemid 38680440)
122. McAleer, J. P. & Kolls, J. K. Mechanisms controlling Th17 cytokine expression and host defense. J. Leukoc. Biol. 90, 263-270 (2011).
123. Ohnmacht, C. et al. Intestinal microbiota, evolution of the immune system and the bad reputation of pro-inflammatory immunity. Cell. Microbiol. 13, 653-659 (2011).
124. Esplugues, E. et al. Control of TH17 cells occurs in the small intestine. Nature 475, 514-518 (2011).
125. Howie, S. E., Horner, P. J., Horne, A. W. & Entrican, G. Immunity and vaccines against sexually transmitted Chlamydia trachomatis infection. Curr. Opin. Infect. Dis. 24, 56-61 (2011).
126. Velin, D. & Michetti, P. Advances in vaccination against Helicobacter pylori. Expert Rev. Gastroenterol. Hepatol. 4, 157-166 (2010).
127. Woodland, D. L. & Kohlmeier, J. E. Migration, maintenance and recall of memory T cells in peripheral tissues. Nature Rev. Immunol. 9, 153-161 (2009).
128. Shortman, K., Lahoud, M. H. & Caminschi, I. Improving vaccines by targeting antigens to dendritic cells. Exp. Mol. Med. 41, 61-66 (2009).
129. Caminschi, I. et al. The dendritic cell subtype-restricted c-type lectin clec9a is a target for vaccine enhancement. Blood 112, 3264-3273 (2008).
130. Fang, Y., Larsson, L., Mattsson, J., Lycke, N. & Xiang, Z. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation. J. Immunol. 185, 2935-2941 (2010).
131. Nakaya, H. I. & Pulendran, B. Systems vaccinology: its promise and challenge for HIV vaccine development. Curr. Opin. HIV AIDS 7, 24-31 (2012).
132. Six, A., Bellier, B., Thomas-Vaslin, V. & Klatzmann, D. Systems biology in vaccine design. Microb. Biotechnol. 5, 295-304 (2011).
133. White, O. J. et al. A genomics-based approach to assessment of vaccine safety and immunogenicity in children. Vaccine 30, 1865-1874 (2012).
134. Pulendran, B. & Ahmed, R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124, 849-863 (2006). (Pubitemid 43261457)
135. Salmi, M. & Jalkanen, S. Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol. Rev. 206, 100-113 (2005). (Pubitemid 41105165)
136. Gorfu, G., Rivera-Nieves, J. & Ley, K. Role of β7 integrins in intestinal lymphocyte homing and retention. Curr. Mol. Med. 9, 836-850 (2009).
137. Mora, J. R. & von Andrian, U. H. Differentiation and homing of IgA-secreting cells. Mucosal Immunol. 1, 96-109 (2008).
138. + dendritic cells. Immunol. Rev. 234, 268-281 (2010).
139. +, antigen sampling cells migrate in lymph and serve classical dendritic cell functions. J. Exp. Med. 206, 3101-3114 (2009).
140. + dendritic cells: master regulators of tolerance? Trends Immunol. 32, 412-419 (2011).
141. + dendritic cells in both tolerogenic and immunogenic T-cell responses. Mucosal Immunol. 5, 150-160 (2011).
142. + IgA plasma cells following mucosal vaccination via estrogen control. J. Immunol. 187, 3044-3052 (2011).
143. Lin, Y., Slight, S. R. & Khader, S. A. Th17 cytokines and vaccine-induced immunity. Semin. Immunopathol. 32, 79-90 (2010).
144. Khader, S. A., Gaffen, S. L. & Kolls, J. K. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2, 403-411 (2009).
145. Belyakov, I. M. & Ahlers, J. D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183, 6883-6892 (2009).
146. Mattsson, J. et al. Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant. J. Immunol. 187, 3641-3652 (2011).
147. Bemark, M. et al. A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development. J. Immunol. 186, 1399-1410 (2011).
148. Dhere, R. et al. A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine 29, A16-A21 (2011).
149. Aylward, R. B. Eradicating polio: today's challenges and tomorrow's legacy. Ann. Trop. Med. Parasitol. 100, 401-413 (2006). (Pubitemid 47050864)
150. Sabin, A. B. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis. 151, 420-436 (1985). (Pubitemid 15103791)
151. Ferreccio, C., Levine, M. M., Rodriguez, H. & Contreras, R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J. Infect. Dis. 159, 766-769 (1989). (Pubitemid 19105635)
152. Shafique, M., Wilschut, J. & de Haan, A. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Vaccine 30, 597-606 (2012).
153. Elson, C. O. Cholera toxin and its subunits as potential oral adjuvants. Curr. Top. Microbiol. Immunol. 146, 29-33 (1989).
154. Agren, L. C., Ekman, L., Lowenadler, B., Nedrud, J. G. & Lycke, N. Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162, 2432-2440 (1999). (Pubitemid 29288873)
155. Muhammad, A., Champeimont, J., Mayr, U. B., Lubitz, W. & Kudela, P. Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications. Expert Rev. Vaccines 11, 97-116 (2012).
156. Thompson, A. L. et al. Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c+ cells and does not correlate with adjuvant-induced in vivo cytokine production. J. Immunol. 188, 2834-2846 (2012).
157. Winstone, N. et al. Enhanced control of pathogenic simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J. Virol. 85, 9578-9587 (2011).